Dr. McElroy graduated from Churchill College Cambridge in 1980 with a first class degree in Natural Sciences and completed a PhD in synthetic organic chemistry before joining Glaxo as a medicinal chemist in 1983. He spent seven years at the Ware and Greenford sites in the UK working on CNS targets and then three years at the Research Triangle Park in North Carolina as a chemistry team leader working on Cardiovascular projects.

Dr. McElroy joined Pfizer in Sandwich in 1993 as a manager in the Medicinal Chemistry department. He became Therapeutic Area Lead for Cardiovascular and Neurodegeneration Research, and later for Tissue Repair managing a portfolio of projects up to First in Human. He was responsible for Chemical technologies and lead a global initiative to harmonize processes and informatics for compound design, synthesis, purification and sample logistics.

In 2009 he became site lead at the Sandwich Site for External Research Solutions group, leading a multidisciplinary team supporting external research and outsourcing. He managed major collaborations in Asia and optimized processes for outsourcing. In 2011 Andy launched TRN – The Research Network Ltd., a new business model dedicated to enabling networked research, providing a flexible framework for the progression of drug discovery and development of novel therapeutic agents. In 2013 Andy led the formation of Eligochem Ltd, a company dedicated to expanding safe druggable space through the design and provision of polar compounds/analogues with good absorption.